Literature DB >> 10485274

Different expression of adhesion molecules on CD34+ cells in AML and B-lineage ALL and their normal bone marrow counterparts.

M De Waele1, W Renmans, K Jochmans, R Schots, P Lacor, F Trullemans, J Otten, N Balduck, K Vander Gucht, B Van Camp, I Van Riet.   

Abstract

The expression of adhesion molecules on CD34+ cells in acute myeloid leukemia (AML) and B-lineage acute lymphoblastic leukemia (B-lineage ALL) was compared with that on the myeloid and B-lymphoid CD34+ cells in normal bone marrow. Bone marrow aspirates of 10 patients with AML, 8 patients with B-lineage ALL and of 6 healthy volunteers were examined. The phenotype of the CD34+ cells was determined with a double immunofluorescence method and flow cytometry. CD34+ cells in AML and B-lineage ALL showed a lower expression of VLA-2 and VLA-3 and a higher expression of ICAM-1 and LFA-3 than their normal bone marrow counterparts. AML CD34+ cells had less L-selectin but more VLA-5 on their surface membrane than normal myeloid CD34+ cells. B-lineage ALL CD34+ cells showed an overexpression of LFA-3. In individual patients deficiencies or over-expression of the beta1 integrin chain, VLA-4, PECAM-1 or HCAM also occurred. An abnormal adhesive capacity of the leukemic cells may influence their proliferation, their localisation and apoptosis. An aberrant expression of adhesion molecules may be used for the detection of minimal residual leukemia in these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485274     DOI: 10.1111/j.1600-0609.1999.tb01767.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

Review 1.  Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.

Authors:  Elaine Coustan-Smith; Dario Campana
Journal:  Best Pract Res Clin Haematol       Date:  2010-10-28       Impact factor: 3.020

2.  STAT3β is a tumor suppressor in acute myeloid leukemia.

Authors:  Petra Aigner; Tatsuaki Mizutani; Jaqueline Horvath; Thomas Eder; Stefan Heber; Karin Lind; Valentin Just; Herwig P Moll; Assa Yeroslaviz; Michael J M Fischer; Lukas Kenner; Balázs Győrffy; Heinz Sill; Florian Grebien; Richard Moriggl; Emilio Casanova; Dagmar Stoiber
Journal:  Blood Adv       Date:  2019-07-09

Review 3.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 4.  Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms.

Authors:  Peter Valent; Irina Sadovnik; Gregor Eisenwort; Harald Herrmann; Karin Bauer; Niklas Mueller; Wolfgang R Sperr; Daniel Wicklein; Udo Schumacher
Journal:  Semin Cancer Biol       Date:  2019-08-10       Impact factor: 15.707

5.  Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs.

Authors:  Allison L Boyd; Clinton J V Campbell; Claudia I Hopkins; Aline Fiebig-Comyn; Jennifer Russell; Jelena Ulemek; Ronan Foley; Brian Leber; Anargyros Xenocostas; Tony J Collins; Mickie Bhatia
Journal:  J Exp Med       Date:  2014-09-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.